GSHP webinar-Should We Be ALZ in on the New Treatments for Alzheimer’s Disease? An Update on the New Monoclonal Antibodies

FREE LIVE CE for GSHP Members! 

Webinar-

Tuesday, February 21, 2023 – 12:00pm-1:00 pm

Should We Be ALZ in on the New Treatments for Alzheimer’s Disease? An Update on the New Monoclonal Antibodies

Presenter:

Suzanne Avant, PharmD, BCPS

PGY2 Ambulatory Care Resident

University of Georgia College of Pharmacy

Objectives for Pharmacists

• Describe the mechanisms of anti-amyloid antibodies on the breakthrough therapy pathway
• Describe anti-amyloid antibody treatment criteria, including strategies to mitigate and monitor for CNS adverse events in eligible patients
• Identify implications of ant-amyloid immunotherapy approval and potential barriers to routine use

Objectives for Pharmacy Technicians

• Describe the mechanisms of anti-amyloid antibodies on the breakthrough therapy pathway
• List anti-amyloid antibody treatment criteria, including strategies to mitigate and monitor for CNS adverse events in eligible patients
• List implications of ant-amyloid immunotherapy approval and potential barriers to routine use
  

Georgia Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1 contact hour (0.1 CEU) submitted to CPE Monitor as early as 1 day after the event and no later than 60 days after the event.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.

UAN # 0228-0000-23-012-L01-P; 0228-0000-23-013-L01-P

This is a knowledge based activity

This is a member service of GSHP.  There is no charge for members to attend.  Dues must be current to receive CE credit.

Non-members will be charged $20 for CE processing

To register:  

https://us02web.zoom.us/webinar/register/WN_KrkxG0OrSFymqz5XFT2xVw